Biodexa Pharmaceuticals (BDRX) Payables (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Payables of $7.3 million for Q4 2025, up 276.99% sequentially from $1.9 million in Q2 2025, and up 46.78% YoY from $5.0 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Payables (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Payables for 13 years, with the latest figure at $7.3 million in Q4 2025.
- Quarterly Payables rose 46.78% year-over-year to $7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.3 million (up 46.78% YoY) and the FY2025 annual result came in at $7.3 million, up 45.49% from the prior year.
- Payables climbed to $7.3 million in Q4 2025 per BDRX's latest filing, from $1.9 million in the prior quarter.
- Over five years, Payables peaked at $7.3 million in Q4 2025 and troughed at $1.8 million in Q4 2022.
- A 5-year average of $3.8 million and a median of $3.1 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables plunged 64.68% in 2022, then soared 272.98% in 2023.
- Over 5 years, Payables stood at $2.2 million in 2021, then fell by 18.97% to $1.8 million in 2022, then jumped by 272.98% to $6.7 million in 2023, then slipped by 25.56% to $5.0 million in 2024, then soared by 46.78% to $7.3 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $7.3 million, $1.9 million, and $5.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Biodexa Pharmaceuticals | 63,168.17 | -11.29 Mn | - | 7.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.32 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Dec 31, 2023 | 6.70 Mn |
| Jun 30, 2023 | 2.65 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Jun 30, 2022 | 1.81 Mn |
| Dec 31, 2021 | 2.22 Mn |
| Jun 30, 2021 | 5.12 Mn |
| Dec 31, 2020 | 3.68 Mn |
| Jun 30, 2020 | 4.89 Mn |
| Dec 31, 2019 | 6.63 Mn |
| Jun 30, 2019 | 3.25 Mn |
| Dec 31, 2018 | 2.71 Mn |
| Jun 30, 2018 | 4.69 Mn |
| Dec 31, 2017 | 10.62 Mn |
| Jun 30, 2017 | 8.49 Mn |
| Dec 31, 2016 | 10.45 Mn |
| Jun 30, 2016 | 8.32 Mn |